Using its proprietary computational disease models, CytoReason will help Merck understand the drug’s mechanism of action, identify patient populations and prioritize indications.
CytoReason, an Israeli company developing computational disease models for more efficient drug discovery and development, announced a collaboration with German multinational science and technology company, Merck, to profile one of its leading immuno-oncology drugs.
Recommended AI News: Kochava Announces Appointment Of Arthur Novarina As Regional Vice President EMEA
Multiple drugs created to cure the same disease have varying effects on certain patient populations depending on the drug’s mechanism of action (MoA) and on patients’ characteristics. CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck’s therapeutic hypothesis, providing a deeper analysis of the drug’s MoA.
The company will analyze data from hundreds of patients from phase 1 and 2 studies to identify relevant patient populations, as well as prioritize tumor types for which the drug may be most effective against.
“We are thrilled to be working with the talented team at Merck,” said David Harel, CEO and Co-founder of CytoReason. “Merck’s rich medical database and expertise in immuno-oncology will enable us to help create more accurate models of the disease with CytoReason’s advanced AI technology. This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer.”
Top Blockchain Insights: “Bitcoin Has No Intrinsic Value”. Then What Gives Bitcoin Value?
[To share your insights with us, please write to sghosh@martechseries.com
Comments are closed.